Navigation Links
Inclinix, Inc. and JSW Life Sciences Announce Formal Strategic Partnership for European Clinical Trial Enrollment

WILMINGTON, N.C., Feb. 21, 2012 /PRNewswire/ -- Inclinix, Inc. and JSW Life Sciences announce today their formal strategic partnership. This partnership places Inclinix offices in Graz, Austria and expands Inclinix by over one hundred enrollment professionals in Eastern and Western Europe.

"As Inclinix has experienced significant growth over the past year, it has been important for us to identify a European partner that shares our philosophy and performance enrollment model," explains J. Tobin Geatz, Inclinix President and CEO. "We are pleased to have such an excellent partner as JSW Life Sciences to support the enrollment of all of our studies in Europe."

The Inclinix Clinical Enrollment Manager (CEM) programs offer a unique approach to global clinical trial enrollment. CEMs provide in-field enrollment support to investigative sites, focusing on identifying qualified study candidates not only from within the sites' practices, but from the surrounding medical and patient communities as well.

Dr. Manfred Windisch, CEO of JSW Life Sciences, states, "We are excited to combine our clinical expertise and native-language teams with Inclinix's enrollment experience. We look forward to many successful enrollment campaigns through this partnership."

About Inclinix
Inclinix, Inc. specializes in customized Phase I-IV clinical enrollment solutions for pharmaceutical, biotechnology, and medical device organizations. Clients benefit from twelve years of experience in multiple therapeutic areas. Inclinix delivers a customized, site-focused approach to patient recruitment ensuring every available study candidate is identified, qualified and enrolled. By combining an in-field approach with highly targeted patient outreach, Inclinix creates effective enrollment strategies within a performance model.

About JSW Life Sciences
JSW Life Sciences is a full service contract research organization. The company performs preclinical as well as clinical research. The preclinical research department focuses on drug development for neurodegenerative diseases. The profound expertise in neuroscience and more than a decade of experience in contract research result in a sustainable advantage for the customer. Validated transgenic & non-transgenic in vivo & in vitro models to address new as well as already established drug targets in neurodegenerative diseases are available. 

The clinical research team ensures an efficient development process from First-in-Man (Phase I) up to and including Post-Marketing-Surveillance-Studies (Phase IV). Our customers benefit from the competent teams at JSW, the use of innovative technology as well as scientific and clinical expertise together with a worldwide network.   

SOURCE Inclinix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Alfacell Corporation to Present at UBS Global Life Sciences Conference
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
(Date:11/27/2015)... , Niederlande, November 27, 2015 ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   Clinical ... --> Clinical Cancer Research vom ...
(Date:11/26/2015)... 26, 2015 Un nuevo enfoque ... para el cáncer avanzado.   --> ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... . --> Clinical Cancer Research . ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and Markets ... "Asia Pacific Cardiac Pacemaker Market Outlook to 2019 - Rise ... the Demand " report to their offering. ... --> Boston scientific and others. ... players including Medtronic, Biotronik, Boston scientific ...
Breaking Medicine Technology:
(Date:11/28/2015)... CA (PRWEB) , ... November 28, 2015 , ... Pixel ... fully customizable media panels to choose from, the possibilities are endless. Users have full ... more. With the ProPanel: Pulse masking effects, users are sure to get heads to ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... new study carried out by the University of Toronto and the University of British ... number of hospitalizations for head injuries. The article explains that part of the reason ...
(Date:11/27/2015)... ... 2015 , ... A team of Swiss doctors has released a report on ... just posted the findings on the website. Click here to read the details ... mesothelioma patients who were treated with chemotherapy followed by EPP surgery. Among the 106 ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... LOS ANGELES, CA (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only ... age of 30 (see Table 1-1 ). More than 3.7 billion people under ... simplex virus type 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection ...
Breaking Medicine News(10 mins):